CSI Market
Sign In | Register

Innovation Pharmaceuticals Inc (CTIX) Quarterly Cash Flow Statement

Quarterly · GAAP · USD millions
Access CTIX Annual Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Innovation Pharmaceuticals Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Sep 30 2023)
3 Months 		(Jun 30 2023) (Mar 31 2023) (Dec 31 2022) (Sep 30 2022)
Operating Activities
Income-0.88
Depreciation & amortization0.00
Amortization of Other Assets0.09
Extraordinary Item, Gain (Loss), Insurance Assets, Accretion Expense0.00
Impairment of Intangible Assets, Finite-lived0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
R & D, Environmental and Other Expense0.00
Gain (Loss) on Disposition of Property Plant Equipment, Excluding Oil and Gas Property and Timber Property0.00
Share-based Compensation0.00
Income (Loss) from Equity Method Investments0.06
Gains (Losses) on Extinguishment of Debt0.00
Issuance Of Stock And Stock Options For Services Compensation Rendered And Charitable Contributions-
Patent Write Off-
Interest Expense-
Write Off Of Deferred Debt Issuance Cost-
Modification Of Series B Convertible Preferred Stock Terms-
Interest Expense Debt-
Change In Fair Value Of Preferred Stock-
Increase Decrease Operating Leases Liability-
Allocating Warrants Proportion Of Value Exercised To Pref Stock Liability-
Operating Lease Impairment Loss-
Interest Expense Preferred Stock-
Change In Fair Value Preferred Stock-
Increase Decrease In Prepaid Expenses And Other Current Assets0.04
Increase Decrease In Accrued Dividend0.01
Income taxes0.00
Gain (Loss) on Investments0.00
Increase (Decrease) in Employee Related Liabilities-0.10
Increase (Decrease) in Accounts Payable0.04
Increase (Decrease) in Accrued Liabilities0.12
Increase (Decrease) in Security Deposits0.00
Increase (Decrease) in Prepaid Expenses, Other0.00
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities-0.06
Discontinued operations0.00
Net Cash flow from Operating Activities-0.68
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Additions To Property Plant And Equipment-
Patent Costs-
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.00
Long-term debt - repayments0.03
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock0.00
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Proceeds From Issuance Of Common Stock Net Of Offering Costs-
Proceeds From Deferred Offering Costs-
Treasury Stock Value Acquired Cost Method-
Convertible Preferred Stock Converted To Other Securities-
Excess Of Exercise Price Of Warrants At850950 Over Fair Value Of-
Sale Of Common Stock Net Of Offering Costs-
Dividend Paid To Preferred Stockholders-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities0.03
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-0.68
Total Cash Flow-0.65
4 historic quarters locked

Sign in to unlock the full Innovation Pharmaceuticals Inc cash flow history.

Sign In Create Free Account

About Innovation Pharmaceuticals Inc Quarterly Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC filings and normalized by CSIMarket.

Source & verification

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001477932-23-008688

Figures are derived from filed reports and may be restated. Historical data is subject to revision.